Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals is well positioned because setmelanotide is showing strengthening efficacy in Prader-Willi syndrome, with BMI reductions improving from 1.84% at 3 months to 3.06% at 6 months and 8 of 10 patients with moderate to severe hyperphagia achieving a clinically meaningful ≥7-point reduction. The data are especially compelling because benefits extend beyond weight to DEXA-based body composition, physical activity, anxiety, and quality-of-life measures, while activity in patients already on Vykat XR suggests differentiated utility rather than simple substitution. Commercially, the company is also seeing a solid U.S. hypothalamic obesity launch with >150 patient start forms in the first 6 weeks, supporting a path toward >$2B revenue by 2030 and setting up multiple catalysts in 2026.

Rhythm Pharmaceuticals is exposed to significant clinical and regulatory uncertainty because setmelanotide is still being tested in later-stage and exploratory trials, where efficacy and safety may not replicate earlier results and new tolerability issues could emerge with longer follow-up. The bearish case assumes only 70% probability of success for Imcivree in approved/derisked indications and just 5% for PWS, bivamelagon, and the broader platform, underscoring how much of the company’s future value depends on outcomes that remain highly uncertain. It also faces intellectual property risk, competition, and long-term pricing pressure, while any setback in sustained efficacy or a safety signal could materially weaken commercial momentum in its U.S.-dependent revenue base.